Why the study?
The short- and long-term thrombogenicity of implant materials remains unpredictable, presenting a significant challenge in cardiovascular disease treatment.
Key points are not available for this paper at this time.
Design
Review
Standardized thrombogenicity testing remains essential for cardiovascular biomaterial safety; leaves open consensus on reproducible standards via joint efforts.
The short- and long-term thrombogenicity of implant materials is still unpredictable, which is a significant challenge for the treatment of cardiovascular diseases. A knowledge-based approach for implementing biofunctions in materials requires a detailed understanding of the medical device in the biological system. In particular, the interplay between material and blood components/cells as well as standardized and commonly acknowledged in vitro test methods allowing a reproducible categorization of the material thrombogenicity requires further attention. Here, the status of in vitro thrombogenicity testing methods for biomaterials is reviewed, particularly taking in view the preparation of test materials and references, the selection and characterization of donors and blood samples, the prerequisites for reproducible approaches and applied test systems. Recent joint approaches in finding common standards for a reproducible testing are summarized and perspectives for a more disease oriented in vitro thrombogenicity testing are discussed.
No takes yet. Share an insight, caveat, or question.
Braune et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: